Arcus Biosciences's total assets for Q4 2024 were $1.15B, a decrease of -8.15% from the previous quarter. RCUS total liabilities were $665.00M for the fiscal quarter, a -3.20% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.